Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients

Maurice Beghetti, Walid Habre, Beat Friedli, Michel Bemer

Abstract

Objective—To assess the effect of inhaled nitric oxide (NO) on severe postoperative pulmonary hypertension in children after surgical repair of a congenital heart defect.

Design—A pilot study of NO administration to 7 consecutive children who required adrenergic support and in whom postoperative mean pulmonary artery pressure was more than two thirds of mean systemic pressure and persisted despite alkalotic hyperventilation.

Setting—Routine care after cardiac surgery for congenital heart disease in a multidisciplinary paediatric intensive care unit.

Methods—Continuous inhalation of NO, initially at 15 ppm. Thereafter, daily attempts at complete weaning or at reducing NO to the lowest effective dose.

Results—In 6 of the 7 children NO inhalation selectively decreased mean (SD) pulmonary artery pressure from 51 (12) to 31 (9) mm Hg (P < 0·05) while mean systemic arterial pressure was unchanged (68 (10) v 71 (7) mm Hg) (NS) and the arteriovenous difference in oxygen content decreased from 6·7 (0·9) to 4·8 (0·8) vol% (P < 0·05). Concomitantly PaO2; increased from 156 (98) to 231 (79) mm Hg (P < 0·05). The seventh child showed no response to NO up to 80 ppm, could not be weaned from cardiopulmonary bypass, and died in the operating room. In responders, attempts at early weaning from NO inhalation always failed and NO at concentrations of less than 10 ppm was continuously administered for a median of 9–5 days (range 4 to 16 days) until complete weaning was possible from a mean dose of 3·9 (2·9) ppm.

Methaemoglobinaemia remained below 2% and nitrogen dioxide concentrations usually ranged from 0·1 to 0·2 ppm. One child later died and five were discharged. A few months after surgery Doppler echocardiography (and catheterisation in one) showed evidence of regression of pulmonary hypertension in all 5.

Conclusions—Inhalation of NO reduced pulmonary artery pressure in children with severe pulmonary hypertension after cardiac surgery and this effect was maintained over several days at concentrations carrying little risk of toxicity.

Keywords: inhaled nitric oxide, pulmonary hypertension, cardiac surgery, children.

Intractable pulmonary hypertension is a major cause of death in the immediate postoperative period after repair of congenital heart defects. In addition to preoperative factors, transient dysfunction of the endothelial cell after cardiopulmonary bypass could affect the physiology of nitric oxide (NO) release1 and such an effect has recently been implicated in the pathogenesis of pulmonary hypertension.2

During cardiac catheterisation in children, inhalation of NO for brief periods at doses of 20–80 ppm reduced the pulmonary vasoconstriction associated with left to right shunts.3 Continuous inhalation at lower doses for 24 hours decreased right to left ductal shunting in neonates with persistent pulmonary hypertension.4 There are occasional reports of NO resolving a postoperative hypertensive crisis.5

There is reluctance to administer inhaled NO in clinical conditions because of its potential toxic effects.6 NO reacts with oxygen to form nitrogen dioxide at a speed that depends on the concentrations of the two gases, and inactivation of NO by haemoglobin can result in important methaemoglobinaemia.

In this pilot study we assessed whether inhalation of NO consistently reduced severe postoperative pulmonary hypertension and whether the concentrations of NO could be kept in a safe range for as long as NO treatment was needed.

Patients and methods

All patients were referred to our centre for elective cardiac surgery; those older than a year were referred from abroad. Two patients had Down's syndrome. Children with congenital heart disease and left to right shunts require an investigation of their pulmonary vascular bed before surgery is planned. We used oxygen consumption derived from a nomogram to estimate cardiac output (from the Fick equation) during cardiac catheterisation and to calculate pulmonary vascular resistance. We used the ratios of pulmonary to systemic vascular resistance (Rp/Rs) and of the respective blood flows (Qp/Qs) as indices of the severity of pulmonary vascular disease to decide upon operability. Postoperatively, management of pulmonary hypertension has so far included hyperventilation induced alkalosis and pharmacological alteration of pulmonary vascular resistance by epoprostenol and tolazoline.

Paediatric Cardiology Unit, Department of Paediatrics, Hôpital Cantonal Universitaire, Geneva, Switzerland
M Beghetti
B Friedli
Paediatric Intensive Care Unit
W Habre
M Bemer
Correspondence to: Dr M Bemer, Pediatric Intensive Care Unit, Hôpital des Enfants, 30 Bd de la Chaux, 1211 Gené 14, Switzerland.
Accepted for publication 28 June 1994

(Br Heart J 1995;73:65–68)
Preoperative characteristics, postoperative course, and outcome of patients

<table>
<thead>
<tr>
<th>Case</th>
<th>Age (months)</th>
<th>Heart defect</th>
<th>Preoperative PVR</th>
<th>Rp/Rs</th>
<th>Initial response to NO</th>
<th>Mean dose of NO (ppm)</th>
<th>Long-term outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>16</td>
<td>VSD, PDA</td>
<td>NA</td>
<td>NA</td>
<td>+</td>
<td>8-5 3-0 3-0</td>
<td>Died</td>
</tr>
<tr>
<td>2</td>
<td>8</td>
<td>ECD*</td>
<td>4-3</td>
<td>24</td>
<td>+</td>
<td>13 9 6 5</td>
<td>Lived</td>
</tr>
<tr>
<td>3</td>
<td>24</td>
<td>VSD</td>
<td>14-1 0-45</td>
<td>85</td>
<td>-</td>
<td>10 1-2 6-0</td>
<td>Lived</td>
</tr>
<tr>
<td>4</td>
<td>23</td>
<td>TA</td>
<td>5-9 2-25</td>
<td>85</td>
<td>-</td>
<td>5-8 1-8 5-1</td>
<td>Lived</td>
</tr>
<tr>
<td>5</td>
<td>12</td>
<td>ECD</td>
<td>6-4 0-71</td>
<td>8-5</td>
<td>-</td>
<td>8-5 7-5 6-0</td>
<td>Lived</td>
</tr>
<tr>
<td>6</td>
<td>6</td>
<td>ECD*</td>
<td>6-4 0-66</td>
<td>8-5</td>
<td>-</td>
<td>8-5 7-5 6-0</td>
<td>Lived</td>
</tr>
<tr>
<td>7</td>
<td>168</td>
<td>VSD</td>
<td>9-3 3-34</td>
<td>8-5</td>
<td>-</td>
<td>8-5 7-5 6-0</td>
<td>Died</td>
</tr>
</tbody>
</table>

PVR, preoperative pulmonary vascular resistance (mm Hg/l/min/m²); Rp/Rs, preoperative pulmonary to systemic vascular resistance ratio; VSD, ventricular septal defect; PDA, patent ductus arteriosus; NA, not available (echocardiographic assessment); ECD, endocardial cushion defect (*Down syndrome); TA, truncus arteriosus.

After we found that NO inhalation was helpful in an infant with severe pulmonary hypertension our institutional review board sanctioned the use of NO treatment after surgical repair of congenital heart disease in children with left to right shunts who had: (a) a mean pulmonary artery pressure that remained consistently higher than 2/3 of mean systemic pressure despite alkaloic hypertentilation at a pH over 7-45 and (b) who had clinical evidence of low output syndrome requiring adrenergic support.

We administered NO (350 ppm in nitrogen, AGA, Pratteln, Switzerland) through the inspiratory limb of a continuous flow, time cycled, pressure limited ventilator (Babylog 8000, Drager AG, Lubeck, Germany). The NO concentration was regulated by a precision flow meter and mixed with the constant flow of the ventilator usually at 20 l/min. NO and nitrogen dioxide concentrations were verified intermittently by chemiluminescence (CLD 700 AL, Eco Physics AG, Durnten, Switzerland) before they entered the ventilator.

We started with 15 ppm NO: if this proved successful we gave the same concentration until the next day, when we first attempted to wean the patient off NO. If there was a rebound in pulmonary hypertension with a decrease in systemic pressure, NO inhalation was resumed at the lowest possible dose capable of maintaining the pulmonary pressure at preweaning values. Each day we attempted weaning, using the same protocol, until complete withdrawal was possible. Ventilation was adapted to keep the pH around 7-45. Adrenergic support was progressively reduced as systemic pressure and diuresis improved. No other vasodilators were used while NO was given or during weaning off NO.

Between two and five months after discharge from the hospital we assessed the result of surgery and measured residual pulmonary hypertension by Doppler echocardiography and, if the result seemed abnormal, by catherisation.

STATISTICAL ANALYSIS

We used a paired sample t test to assess the effects of NO inhalation and linear regression analysis to analyse the relation between variables and the effect of NO on pulmonary pressure. A P value of < 0-05 was regarded as significant.

Results

The table shows the characteristics of the seven consecutive patients. Before operation pulmonary vascular resistance was decreased in all children, with values ranging from 4-3 to 14-1 mm Hg/l/min/m². After operation pulmonary hypertension was present as soon as the patients came off cardiopulmonary bypass. All patients had signs of right ventricular failure requiring inotropic support (five with adrenaline (0-8 (0-1) μg/kg/min) and two with dobutamine (15 μg/kg/min). In addition, in three children, the pericardium and thorax had to be left open. All children were given dopamine (5 μg/kg/min). Mean fractional inspired oxygen was 0-81 (0-25) and a raised mean pulmonary arterial pressure 

\[ P = 2136 (537) \] mmHg/ml/min was required to maintain a mean pH of 7-48 (0-03). In six of the seven children, inhalation of NO resulted in an immediate decrease in mean pulmonary arterial pressure from a mean of 51 (12) to 31 (9) mm Hg (P < 0-05) without any change in mean systemic arterial pressure (68 (10) v 71 (7) mm Hg). The drop in pulmonary artery pressure (ΔP) with NO correlated positively with the postoperative mean pulmonary artery pressure (PAP) (fig 1) and showed a tendency to an inverse correlation with the preoperative systemic to pulmonary resistance ratio (ΔP = -22 Rp/Rs + 26, \( R^2 = 0-53, P = 0-07 \) (fig 2). In one patient, who had a thermodilution catheter in place, the pulmonary blood flow increased from 1-5 to 1-8 l/min. In the five other children, the arteriovenous difference in oxygen content decreased from 6-7 (0-9) to 4-8 (0-8) vol%, I was 0-05. \( PaO_2 \), increased from 158 (98) to 2136 (79) mm Hg (P < 0-05 with little change in \( FiO_2 \). (0-81 (0-25) to 0-70 (0-23) NS). There was no significant decrease in \( PaCO_2 \), (31 (9) to 27 (5) mm Hg, NS) and minute ventilation was unchanged (2136 (537) vs 2036 (463) mmHg/min). Attempts to wean all the children off NO after 24 hours failed, resulting in an immediate increase in pulmonary arterial pressure (32 (5) to 51 (3) mm Hg, P < 0-05) with a concomitant decrease in mean systemic arterial pressure from 64 (6) to 57 (9) mm Hg (P < 0-05), both effects resolved when inhalation of NO was resumed. Figure 3 shows the effect of introducing NO on both pulmonary and systemic arterial pressures and the first attempt at weaning off NO after 24 hours in the six responders. The lowest concentrations of NO able to maintain pulmonary artery pressure at preweaning values were all above 15 ppm and averaged 0-9 (1-2) ppm on day 2 and 5-4 (4-0) ppm on day 4. Maintenance of inhaled NO at concentrations as low as 0-8 ppm was occasionally effective (fig 4): in one patient, NO was given through nasal prongs after extubation. Complete weaning from a mean dose of 3-9 (2-9) ppm was achieved after a median of 9-5 days (range 4-16) in all patients. In the two
patients in whom the thorax had to be left open after surgery the chest eventually could be closed.

Patient 7 could not come off cardiopulmonary bypass and administration of NO was started in the operating room. Despite inhalation of concentrations from 15 up to 80 ppm, pulmonary artery pressure remained equal to systemic pressure and both were around 40 mm Hg despite massive adrenergic support. The child eventually died and a lung biopsy specimen showed advanced vascular disease with recanalisation of obliterative lesions and a chronic interstitial pneumonitis.

The level of methaemoglobinaemia was always < 2% and nitrogen dioxide concentrations measured in the expiratory circuit rarely exceeded 0·5 ppm (range 0·1–0·2 ppm). One patient later died of a cause unrelated to cardiovascular pathology. The five patients discharged from the hospital were evaluated 2–5 months after operation and showed good results. Of the three with preoperative signs of severe pulmonary artery hypertension two had a decrease in systolic pulmonary pressure estimated from tricuspid pulmonary pressure estimated from tricuspid pulmonary regurgitation at echocardiography (from 78 to 45 mm Hg and 60 to 40 mm Hg respectively) and one showed a decrease in Rp/Rs at catheterisation from 0·45 to 0·33. In the two last patients, either Rp/Rs (0·31) or systolic pressure (40 mm Hg) resembled the preoperative value.

Discussion

In this pilot study low doses of inhaled NO consistently reduced severe postoperative pulmonary hypertension in children after repair of congenital heart defects. In such patients NO has the advantage of selectively causing pulmonary vasodilatation, with a rapid decrease in right ventricular afterload, rather than improving the ventilation perfusion mismatch. None the less, the rise in Pao2 described in patients with diffuse lung injury2 was also seen. An increase in pulmonary blood flow was measured in one child who had a thermolubation catheter in place and was indicated in the other patients by a significant decrease in the arteriovenous oxygen content difference. Overall haemodynamic improvement was later indicated by the progressive ability to withdraw adrenergic support. All these effects accord with the recent findings of Wessel et al who showed that much of the increase in pulmonary vascular resistance after cardiac surgery is related to endothelial cell dysfunction and that it can be overcome by treatment with NO.2 Additional support for this hypothesis comes from the significant drop in pulmonary pressure that followed NO treatment and correlated positively with the height of postoperative pulmonary artery pressure. This drop tended to correlate negatively with the preoperative pulmonary to systemic vascular resistance ratio. In our patients, these effects were induced by lower concentrations than described previously2,4 and often, only minute amounts (1 to 4 ppm) were required to maintain low pulmonary artery pressure. Low doses of NO were also effective in lung diseases.13

Our selection criteria were defined to apply to children with the most severe postoperative pulmonary hypertension that did not respond to alkalosis-induced pulmonary vasodilatation, which has been shown to act independently of the NO pathway.14 Indeed, we encountered pulmonary hypertension resistant to NO: concentrations up to 80 ppm for one hour were not able to decrease pulmonary pressure in one child with advanced obliterative vascular disease who died in the operating room. A progressive decline in the vasodilator response of the pulmonary vascular bed first to acetylcysteine11 and later to nitrous vasodilators was seen in children with advanced pulmonary vascular disease. Nevertheless, a test with NO, even at high doses, can be attempted because there is no risk of a drop in systemic pressure. Also in future, combination of NO with other vasodilators might prove beneficial, as suggested by the simultaneous administration of NO and epoprostenol.9

Unlike the report of an earlier case8 attempts at abrupt weaning in the first 24 hours failed in all these children and resulted in a considerable rise in pulmonary artery pressure within minutes accompanied by a fall...
in systemic arterial pressure. This meant that during tracheal suctioning a second delivery system had to be used to administer NO. The decision of when and how to weaning is arbitrary. In all cases a tolerable increase in pulmonary artery pressure without systemic haemoglobin desaturation or a drop in systemic pressure was seen only after several days and when the dose of NO had been low. In one case after extubation administration of NO was continued through nasal prongs and was well tolerated. There are two possible explanations why weaning from administration had to be done gradually: (a) a possible down-regulation of the endogenous production of NO once inhalation has been started,\(^2\) and (b) progressive recovery from the cell dysfunction over several days.\(^2\)

The dose of inhaled NO that reduced and maintained low pulmonary artery pressure was well below the 25 ppm allowed by the National Institute for Occupational Safety and Health.\(^17\) Concentrations of methaemoglobin were measured daily and never reached clinically important values. However, the toxicity of NO is mostly associated with its transformation into nitrogen dioxide which can damage the lungs. Low doses of NO and high ventilator flow rates minimises the residence time of the NO/O\(_2\) mixture in the ventilator circuitry. Nitrogen dioxide concentrations rarely exceeded 0.5 ppm, which is 10 times lower than the upper limit tolerated.\(^18\) The concentrations of 0.1 to 0.2 ppm of nitrogen dioxide that we recorded are commonly detected in the ambient air of many western industrial cities during the winter.\(^19\)

Pulmonary hypertension resolved in six of seven patients given NO. One child later died from an episode of severe anoxia unrelated to his cardiovascular pathology. The five other patients were discharged. All were doing well clinically and showing signs of regression of their pulmonary hypertension at echocardiography or catheterisation several months later.

Low doses of inhaled NO reduced pulmonary hypertension after cardiac surgery in most of these patients. This treatment for a potentially life threatening condition carried little risk of toxicity. This knowledge should help workers to design clinical trials to assess the place of inhaled NO in the complex treatment of pulmonary hypertension after cardiac surgery in children.

---

Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients.

M. Beghetti, W. Habre, B. Friedli and M. Berner

*Br Heart J* 1995 73: 65-68
doi: 10.1136/hrt.73.1.65

Updated information and services can be found at:
[http://heart.bmj.com/content/73/1/65](http://heart.bmj.com/content/73/1/65)

These include:

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)